Literature DB >> 32676144

Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ.

Jonathan A Spencer1,2, Ian R Baldwin1, Nick Barton1, Chun-Wa Chung1, Máire A Convery1, Christopher D Edwards1, Craig Jamieson2, David N Mallett1, James E Rowedder1, Paul Rowland1, Daniel A Thomas1, Charlotte J Hardy1.   

Abstract

A macrocyclization approach has been explored on a series of benzoxazine phosphoinositide 3-kinase δ inhibitors, resulting in compounds with improved potency, permeability, and in vivo clearance while maintaining good solubility. The thermodynamics of binding was explored via surface plasmon resonance, and the binding of lead macrocycle 19 was found to be almost exclusively entropically driven compared with progenitor 18, which demonstrated both enthalpic and entropic contributions. The pharmacokinetics of macrocycle 19 was also explored in vivo, where it showed reduced clearance when compared with the progenitor 18. This work adds to the growing body of evidence that macrocyclization could provide an alternative and complementary approach to the design of small-molecule inhibitors, with the potential to deliver differentiated properties.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32676144      PMCID: PMC7357223          DOI: 10.1021/acsmedchemlett.0c00061

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.

Authors:  Kenneth Down; Augustin Amour; Ian R Baldwin; Anthony W J Cooper; Angela M Deakin; Leigh M Felton; Stephen B Guntrip; Charlotte Hardy; Zoë A Harrison; Katherine L Jones; Paul Jones; Suzanne E Keeling; Joelle Le; Stefano Livia; Fiona Lucas; Christopher J Lunniss; Nigel J Parr; Ed Robinson; Paul Rowland; Sarah Smith; Daniel A Thomas; Giovanni Vitulli; Yoshiaki Washio; J Nicole Hamblin
Journal:  J Med Chem       Date:  2015-09-03       Impact factor: 7.446

2.  Ligand preorganization may be accompanied by entropic penalties in protein-ligand interactions.

Authors:  Aaron P Benfield; Martin G Teresk; Hilary R Plake; John E DeLorbe; Laura E Millspaugh; Stephen F Martin
Journal:  Angew Chem Int Ed Engl       Date:  2006-10-20       Impact factor: 15.336

3.  Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.

Authors:  Shawn J Stachel; Craig A Coburn; Sethu Sankaranarayanan; Eric A Price; Guoxin Wu; Michelle Crouthamel; Beth L Pietrak; Qian Huang; Janet Lineberger; Amy S Espeseth; Lixia Jin; Joan Ellis; M Katharine Holloway; Sanjeev Munshi; Timothy Allison; Daria Hazuda; Adam J Simon; Samuel L Graham; Joseph P Vacca
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 4.  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?

Authors:  Fabrizio Giordanetto; Jan Kihlberg
Journal:  J Med Chem       Date:  2013-09-17       Impact factor: 7.446

5.  Dialkylbiaryl Phosphines in Pd-Catalyzed Amination: A User's Guide.

Authors:  David S Surry; Stephen L Buchwald
Journal:  Chem Sci       Date:  2011       Impact factor: 9.825

6.  Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.

Authors:  Anthony D William; Angeline C-H Lee; Stéphanie Blanchard; Anders Poulsen; Ee Ling Teo; Harish Nagaraj; Evelyn Tan; Dizhong Chen; Meredith Williams; Eric T Sun; Kee Chuan Goh; Wai Chung Ong; Siok Kun Goh; Stefan Hart; Ramesh Jayaraman; Mohammed Khalid Pasha; Kantharaj Ethirajulu; Jeanette M Wood; Brian W Dymock
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

7.  Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis.

Authors:  Antonia F Stepan; Gregory W Kauffman; Christopher E Keefer; Patrick R Verhoest; Martin Edwards
Journal:  J Med Chem       Date:  2013-08-21       Impact factor: 7.446

8.  Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.

Authors:  Nico J de Mol; Frank J Dekker; Isabel Broutin; Marcel J E Fischer; Rob M J Liskamp
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

9.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.

Authors:  Yasuo To; Kazuhiro Ito; Yasuo Kizawa; Marco Failla; Misako Ito; Tadashi Kusama; W Mark Elliott; James C Hogg; Ian M Adcock; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

10.  Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods.

Authors:  Yasmina S N Day; Cheryl L Baird; Rebecca L Rich; David G Myszka
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.